the last decade, most have not been widely studied in populations with chronic kidney disease under routine care. Linagliptin, a recently marketed dipeptidyl peptidase 4 (DPP-4) inhibitor, is the only agent in the U.S. that does not require dose adjustment in patients with diabetes mellitus type 2 (T2DM) and renal impairment. We sought to describe baseline kidney function and other key characteristics among patients with diabetes mellitus type 2 (T2DM) initiating linagliptin and other diabetes medications, and to explore prescribing patterns among T2DM patients with moderate to severe renal impairment before and after the launch of linagliptin.
Design: Using a population-based cohort study design nested in a large U.S. commercial healthcare dataset linked to laboratory values, we described characteristics of T2DM patients initiating linagliptin and other diabetes medications between May 2011 (launch of linagliptin) and September 2015. We also explored prescribing trends among T2DM patients with moderate to severe renal impairment (ICD-9 diagnosis code 585.3x-6x) who initiated linagliptin and other diabetes medications between January 2006 to September 2015 (before and after the launch of linagliptin). We sought to describe baseline kidney function and other key characteristics among T2DM patients initiating linagliptin and other diabetes medications and to explore prescribing patterns among T2DM patients with moderate to severe renal impairment before and after the launch of linagliptin.
Patients

| METHODS
Within a large U.S. commercial insurance data set (Clinformatics Other DPP-4i, other DPP-4 inhibitors (i.e alogliptin, saxagliptin and sitagliptin); 2nd gen SU, 2nd generation sulphonylureas (i.e glipizide, glimepiride, glyburide); GLP-1 RA, GLP-1 receptor agonists (i.e albiglutide, dulaglutide, exenatide, liraglutide); glitazones, thiazolidinediones (i.e rosiglitazone, pioglitazone); glinides, meglitinides (i.e nateglinide, repaglinide); SGLT2i, SGLT-2 inhibitors (i.e canagliflozin, dapagliflozin, empagliflozin); SD, standard deviation; CKD, chronic kidney disease, assessed through ICD-9 diagnosis codes; HbA1c, haemoglobin A1c; eGFR, estimated glomerular filtration rate.
| RESULTS
a As measured by the Romano modification of the Charlson comorbidity score. 4 and kidney dysfunction in routine care are limited, and current guidelines do not specifically recommend the preferential use of these agents over alternative treatments in this population. 5, 8 In the light of this, further investigation of the safety and effectiveness of DPP-4 inhibitors in the routine care of T2DM patients with renal impairment is sorely needed to either corroborate or discourage current prescribing patterns.
